WuXi Biologics Initiated Construction of a
State-of-the-Art Integrated ADC Solution Center
WUXI, China, June 20, 2018 – WuXi Biologics
(2269.HK), a leading global open-access biologics technology platform company
offering end-to-end solutions for biologics discovery, development and
manufacturing, announced today that it has started the construction of a
state-of-the-art integrated biologics conjugate solution center in Wuxi city,
China.
This $20 million
6,000 square meter facility will be operational in 2019 and provide integrated
solutions from concept to commercialization for biologics conjugates including
Antibody-Drug Conjugates (ADCs) and other protein conjugates.
ADCs are complex
molecules composed of an antibody linked to a biologically active cytotoxic
drug and are becoming emerging treatments of targeted tumor therapy. WuXi
Biologics plans to build this site into a world-class ADC R&D and
manufacturing platform which will meet US, EU and Chinese cGMP standards.
“I am very excited
about this new investment in ADCs,” Dr. Chris Chen, CEO of WuXi Biologics said.
“In collaboration with chemistry division of WuXi AppTec Group, WuXi Biologics
is one of the few global companies that can provide the one-stop service to
global partners for antibodies, small molecule payloads, ADCs drug substance
and drug products. Our vision is to empower any global partners to develop any
ADC to benefit patients.”
藥明生物開建全球領先的抗體偶聯藥物（ADC）一體化研發生產中心
中國無錫，2018年6月20日——全球領先的生物製藥技術平台公司藥明生物（WuXi Biologics, 2269.HK）今日宣布，公司計劃投資2,000萬美元在無錫國家高新技術產業開發區籌建全球領先的生物偶聯藥物一體化研發生產中心。
這是藥明生物計劃建設的第三個生物製劑生產基地（Drug Product 3, DP3），旨在為國內外合作夥伴提供包括抗體偶聯藥物（Antibody-Drug Conjugates, ADCs）在內的生物偶聯藥物（Biologics-Drug Conjugates）一體化研發生產服務，推動全球創新生物偶聯藥物從概念到商業化生產的研發全過程。該中心規劃建築面積達6,000平方米，預計將於2019年完工並投入使用。
抗體偶聯藥物（ADCs）是一類通過連接子（Linker）將具有腫瘤細胞殺傷力的小分子藥物（Drug）偶聯至單克隆抗體（Antibody）上而產生的複雜藥物，也是近年來腫瘤靶向治療領域的一種新興療法。藥明生物將把該中心打造成為符合美國、歐盟以及中國cGMP標準的國際一流抗體偶聯藥物研發生產平台，從而更好地服務全球合作夥伴。
“我非常高興能在抗體偶聯藥物領域開展新投資。”藥明生物首席執行官陳智勝博士表示，“借助與藥明康德集團旗下化學藥業務部門的通力合作，藥明生物將成為全球範圍內為數不多能提供從抗體、活性小分子、抗體偶聯藥物原液到製劑一站式服務的企業。我們致力於為全球合作夥伴賦能，幫助他們開發任意一種抗體偶聯藥物，造福全球病患。”
沒有留言:
發佈留言